Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

967 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States.
Li Q, Chitnis A, Hammer M, Langer J. Li Q, et al. Among authors: hammer m. Diabetes Ther. 2014 Dec;5(2):579-90. doi: 10.1007/s13300-014-0084-9. Epub 2014 Sep 26. Diabetes Ther. 2014. PMID: 25256818 Free PMC article.
Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.
Bode BW, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, Garber A; LEAD-3 Study Group. Bode BW, et al. Among authors: hammer m. Diabetes Obes Metab. 2010 Jul;12(7):604-12. doi: 10.1111/j.1463-1326.2010.01196.x. Diabetes Obes Metab. 2010. PMID: 20590735 Free PMC article. Clinical Trial.
Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study.
Buysman EK, Liu F, Hammer M, Langer J. Buysman EK, et al. Among authors: hammer m. Adv Ther. 2015 Apr;32(4):341-55. doi: 10.1007/s12325-015-0199-z. Epub 2015 Apr 2. Adv Ther. 2015. PMID: 25832470 Free PMC article.
Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study.
Chitnis AS, Ganz ML, Benjamin N, Langer J, Hammer M. Chitnis AS, et al. Among authors: hammer m. Adv Ther. 2014 Sep;31(9):986-99. doi: 10.1007/s12325-014-0153-5. Epub 2014 Sep 23. Adv Ther. 2014. PMID: 25245811 Free PMC article.
Adult patients with T2D (≥18 years and BMI≥ 25 kg/m(2)) and A1C >7% at baseline who started liraglutide between January 1, 2010 and January 31, 2013 and who did not use insulin or a glucagon-like peptide-1 analog 12 months before initiating liraglutide (N = 3,005) were …
Adult patients with T2D (≥18 years and BMI≥ 25 kg/m(2)) and A1C >7% at baseline who started liraglutide between January 1, 2010 an …
Variation in the risk of progression between glycemic stages across different levels of body mass index: evidence from a United States electronic health records system.
Blume SW, Li Q, Huang JC, Hammer M, Graf TR. Blume SW, et al. Among authors: hammer m. Curr Med Res Opin. 2015 Jan;31(1):115-24. doi: 10.1185/03007995.2014.971356. Epub 2014 Oct 16. Curr Med Res Opin. 2015. PMID: 25266974
The adjusted hazard ratios for normal to PreD progression ranged from 1.8 (25 ≤ BMI < 30 kg/m(2)) to 6.5 (BMI ≥ 40 kg/m(2)); for PreD to T2D, 1.3 to 2.9; for normal to T2D, 1.8 to 9.5; and for PreD to normal, ∼0.7 across all BMI. ...
The adjusted hazard ratios for normal to PreD progression ranged from 1.8 (25 ≤ BMI < 30 kg/m(2)) to 6.5 (BMI ≥ 40 kg/m(2)) …
The Economic Burden of Obesity by Glycemic Stage in the United States.
Li Q, Blume SW, Huang JC, Hammer M, Graf TR. Li Q, et al. Among authors: hammer m. Pharmacoeconomics. 2015 Jul;33(7):735-48. doi: 10.1007/s40273-014-0248-5. Pharmacoeconomics. 2015. PMID: 25564434 Free PMC article.
We predicted the adjusted incremental annual costs associated with high BMI, relative to normal BMI (18.5-24.9 kg/m(2)). RESULTS: We identified 48,344 adults in normal glycemic stage, 3,085 in the PreD stage, and 9,526 in the T2D stage (mean age 46, 58, and 60 years, respe …
We predicted the adjusted incremental annual costs associated with high BMI, relative to normal BMI (18.5-24.9 kg/m(2)). RESULTS: We …
Prevalence and healthcare costs of obesity-related comorbidities: evidence from an electronic medical records system in the United States.
Li Q, Blume SW, Huang JC, Hammer M, Ganz ML. Li Q, et al. Among authors: hammer m. J Med Econ. 2015;18(12):1020-8. doi: 10.3111/13696998.2015.1067623. Epub 2015 Sep 4. J Med Econ. 2015. PMID: 26134917

Adults with < 2 years of data, who were underweight (body mass index (BMI) < 18.5 kg/m(2)), or had diseases causing major weight change (e.g., malignancy) during the study period (i.e., continuous enrollment in health plans) were excluded. ...RESULTS: This study iden

Adults with < 2 years of data, who were underweight (body mass index (BMI) < 18.5 kg/m(2)), or had diseases causing major weigh

Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.
Lee WC, Conner C, Hammer M. Lee WC, et al. Among authors: hammer m. Curr Med Res Opin. 2011 May;27(5):897-906. doi: 10.1185/03007995.2011.559444. Epub 2011 Feb 25. Curr Med Res Opin. 2011. PMID: 21348806 Clinical Trial.
Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
Lee WC, Conner C, Hammer M. Lee WC, et al. Among authors: hammer m. Clin Ther. 2010 Sep;32(10):1756-67. doi: 10.1016/j.clinthera.2010.08.010. Clin Ther. 2010. PMID: 21194600
Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study.
Schmidt WE, Christiansen JS, Hammer M, Zychma MJ, Buse JB. Schmidt WE, et al. Among authors: hammer m. Diabet Med. 2011 Jun;28(6):715-23. doi: 10.1111/j.1464-5491.2011.03276.x. Diabet Med. 2011. PMID: 21388442 Free PMC article. Clinical Trial.
967 results
Jump to page
Feedback